新辅助治疗在局部晚期食管鳞癌中的应用  

Neoadjuvant therapy in locally advanced esophageal squamous cell carcinoma

作　　者：陈锐 傅剑华[1] Chen Rui;Fu Jianhua(Department of Thoracic Surgery,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Guangdong Esophageal Cancer Institute,Collaborative Innovation Center for Cancer,Medicine,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心胸外科、华南肿瘤学国家重点实验室、广东省食管癌研究所肿瘤医学协同创新中心,广州510060

出　　处：《中华胃肠外科杂志》2023年第4期312-318,共7页Chinese Journal of Gastrointestinal Surgery

基　　金：国家自然科学基金(82272881)。

摘　　要：单纯手术对于局部晚期食管鳞癌的疗效不尽如人意。为提高其疗效,世界各地学者探究多种综合治疗模式,特别是新辅助治疗模式,包括新辅助化疗、新辅助放化疗、新辅助化疗联合免疫治疗以及新辅助放化疗联合免疫治疗等。随着免疫时代的到来,新辅助化学治疗联合免疫治疗和新辅助放化疗联合免疫治疗的方法备受研究者关注。为此,本文拟对以手术为主的食管鳞癌新辅助治疗模式这一热点问题进行讨论。The efficacy of surgery alone for locally advanced esophageal squamous cell carcinoma(ESCC)is limited.In-depth studies concerning combined therapy for ESCC have been carried out worldwide,especially the neoadjuvant treatment model,including neoadjuvant chemotherapy(nCT),neoadjuvant chemoradiotherapy(nCRT),neoadjuvant chemotherapy combined with immunotherapy(nICT),neoadjuvant chemoradiotherapy combined with immunotherapy(nICRT),etc.With the advent of the immunity era,nICT and nICRT have attracted much attention from researchers.An attempt was thus made to take an overview of the evidence-based research advance regarding the neoadjuvant therapy of ESCC.

关 键 词：食管鳞癌 局部晚期 新辅助治疗 循证医学 

分 类 号：R735.1[医药卫生—肿瘤]